

Application No.: Not Yet Assigned


Docket No.: G0365.0353/P353

**REMARKS**

This Preliminary Amendment is being filed in order to reduce the filing fee and to place the application in better form for examination. Applicants reserve the right to pursue the original claims and other claims in this application and in other applications. Favorable action on the present application is solicited.

Dated: March 1, 2002

Respectfully submitted,

By 

Mark J. Thronson

Registration No. 33,082

DICKSTEIN SHAPIRO MORIN &

OSHINSKY LLP

2101 L Street NW

Washington, DC 20037-1526


(202) 785-9700

Attorneys for Applicant




Application No.: Not Yet Assigned


Docket No.: G0365.0353/P353



wherein A, B, Q, R-R<sup>4</sup>, m, n, p and q are as defined in [any preceding] claim 1; L is a polymeric, oligomeric or copolymeric bridging group which comprises polymer selected from the group consisting of acrylic polymers, alkylene polymers, urethane polymers, polyethylene glycols, polyamides, polysaccharides and polyesters; a is an integer of 1 to 100000, b and c are integers of 0 to 100000 and s is an integer of 0 to 100; D comprises one or more structures individually selected from the group consisting of,



wherein R<sup>14</sup> and R<sup>14'</sup> comprise groups individually selected from the same groups as defined for R or may comprise a structure selected from the group consisting of



wherein n is an integer of 0-100, R<sup>15</sup> is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl, R<sup>16</sup> to R<sup>18</sup> are individually selected from the group consisting of H, C<sub>1</sub>-C<sub>12</sub>

alkyl, C<sub>1</sub>-C<sub>12</sub> alkenyl, C<sub>6</sub>-C<sub>18</sub> aryl, C<sub>7</sub>-C<sub>18</sub> aralkyl, C<sub>5</sub>-C<sub>18</sub> cycloalkyl or is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>1</sub>-C<sub>12</sub> alkenyl, C<sub>6</sub>-C<sub>18</sub> aryl, C<sub>7</sub>-C<sub>18</sub> aralkyl, C<sub>6</sub>-C<sub>18</sub> cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms, a pendent group comprising a linker unit, for example a peptide linkage or a unit having the structure (I) or a leaving group; R<sup>13</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>1</sub>-C<sub>12</sub> alkenyl, C<sub>6</sub>-C<sub>18</sub> aryl, C<sub>7</sub>-C<sub>18</sub> aralkyl, C<sub>5</sub>-C<sub>18</sub> cycloalkyl or is selected from the group consisting of C<sub>1</sub>-C<sub>12</sub> alkyl, C<sub>1</sub>-C<sub>12</sub> alkenyl, C<sub>6</sub>-C<sub>18</sub> aryl, C<sub>7</sub>-C<sub>18</sub> aralkyl, C<sub>6</sub>-C<sub>18</sub> cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms, R<sup>13</sup> optionally incorporating a linker unit, for example a peptide linkage or a unit having the structure (I).

11. (Amended) A polymer according to claim 9 [or 10], wherein s is an integer of 1 to 10, preferably 1.

12. (Amended) a polymer according to claim 9[, 10 or 11], wherein at least one of R<sup>14</sup> to R<sup>24</sup> incorporates a cleavable bond, preferably a group (I) or one or more peptide bonds.


13. (Amended) A polymer according to [any preceding] claim 9, wherein the polymer is conjugated to a bioactive agent, preferably an anti cancer agent, most preferably, doxorubicin, daunomycin or taxol.

14. (Amended) A polymer according to [any preceding] claim 9, wherein the molecular weight is in the range 0.5kDa-400kDa.

15. (Amended) A polymer according to [any preceding] claim 2, having the structure


Application No.: Not Yet Assigned

Docket No.: G0365.0353/P353




wherein PEG is a polyethylene glycol group, or derivative thereof, having a molecular weight in the range 500 Da-100kDa and u is an integer in the range of 1-10000.

16. (Amended) A polymer according to [any of claims] claim 1 [to 14], having the structure



wherein PEG is a polyethylene glycol group having a molecular weight in the range 500 Da-100kDa or derivative thereof, and u is an integer in the range of 1-10000.

17. (Amended) A prepolymer comprising the structure



wherein A, B, Q, R-R<sup>3</sup>, m, n, p and q are as defined in [any preceding] claim 2; R<sup>13</sup> and L are as defined in [any of claims] claim 9 [to 16]; A', B', Q', R<sup>1</sup>-R<sup>4</sup>, m', n', p', and q' are selected from the groups as defined for A, B, Q, R<sup>1</sup>-R<sup>4</sup>, m, n, p and q respectively; E and K are selected from the group consisting of hydrogen, an activating group or a protecting



a) introducing a polymer as comprising a structure (I) or (II) as defined in [any preceding] claim 9, to an environment having a pH of less than 6.5,

b) cleaving said polymer.

25. (Amended) A method for releasing a bioactive agent comprising the steps of

a) introducing a conjugate comprising a structure (I) or (II) as defined in [any preceding] claim 9, and a bioactive agent to an environment having a pH of less than 6.5,

c) cleaving the bioactive agent from the linker group by acid or enzymic hydrolysis,

d) optionally additionally cleaving the polymer by acid or enzymic hydrolysis.

26. (Amended) A composition comprising at least one polymer as defined in [any of claims] claim 1 [to 16] and a carrier.

27. (Amended) A composition comprising at least one polymer as defined in [any of claims] claim 1 [to 16] and a pharmaceutically acceptable excipient.

28. (Amended) Use of a polymer as defined in [any of claims] claim 1 [to 16] as a pharmaceutical excipient.